Product Code: GVR-1-68038-785-8
Structural Heart Devices Market Growth & Trends:
The global structural heart devices market size is expected to reach USD 12.8 billion by 2030, registering a CAGR of 9.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is expected to witness exponential growth over the next 8 years due to the rapid increase in cardiovascular conditions and increasing power of healthcare expenditure.
The defects are mostly present at birth, thereby directly affecting the under-5 mortality rate of a country. Therefore, rigorous actions are being undertaken by various government bodies across the globe to increase access to treatment. The Centers for Disease Control and Prevention have a public action plan for efficient management of cardiac conditions.
In addition, other organizations are working on improving the scenario for structural heart disease treatment. For instance, in November 2016, the Cardiovascular Research Foundation (CRF) announced a launch of a journal focusing on the diagnosis and treatment of structural heart defects. It was titled Structural Heart: The Journal of the Heart Team and is expected to be launched in May 2017. This is expected to trigger research & development activities along with capital invested in this field, resulting in technological advancements.
Structural Heart Devices Market Report Highlights:
- Surgical Aortic Valve Replacement (SAVR) dominated the market in 2022, closely followed by Transcatheter Aortic Valve Replacement (TAVR). It can be attributed to the longest presence of the technique in the treatment regimen of aortic stenosis
- Left Atrial Appendage Closure (LAAC) is anticipated to be one of the fastest-growing segment owing to the minimally invasive nature of the procedure. It also helps in the reduction of risk of stroke, thus is projected to have a higher demand
- Geographically, North America held the largest structural heart devices market share in 2016 and is expected to maintain its position during the forecast period. A high prevalence of cognitive heart diseases is the key reason for this dominance. Moreover, the mandatory CCHD screening for newborns imposed by the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) in September 2014 also contributes to the growth in this region
- Asia Pacific is also expected to witness rapid growth over the forecast period. The improved access and capability for treatments in this region is the key reason for this growth
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Regional scope
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Structural Heart Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Structural Heart Devices Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Structural Heart Devices Market: Type Estimates & Trend Analysis
- 4.1. Structural Heart Devices Market: Key Takeaways
- 4.2. Structural Heart Devices Market: Type Movement & Market Share Analysis, 2022 & 2030
- 4.3. SAVR (Surgical Aortic Valve Replacement)
- 4.3.1. SAVR (Surgical Aortic Valve Replacement) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. TAVR (Transcatheter Aortic Valve Replacement)
- 4.4.1. TAVR (Transcatheter Aortic Valve Replacement) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Mitral Repair (Annuloplasty)
- 4.5.1. Mitral repair (annuloplasty) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. LAAC (Left Atrial Appendage Closure)
- 4.6.1. LAAC (Left Atrial Appendage Closure) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Structural Heart Devices Market: Regional Estimates & Trend Analysis
- 5.1. Regional Outlook
- 5.2. Structural Heart Devices Market by Region: Key Takeaways
- 5.3. North America
- 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.3.2. U.S.
- 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.3.3. Canada
- 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4. Europe
- 5.4.1. UK
- 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.2. Germany
- 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.3. France
- 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.4. Italy
- 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.5. Spain
- 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.6. Sweden
- 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.7. Norway
- 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.4.8. Denmark
- 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5. Asia Pacific
- 5.5.1. Japan
- 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5.2. China
- 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5.3. India
- 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5.4. Australia
- 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5.5. Thailand
- 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.5.6. South Korea
- 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.6. Latin America
- 5.6.1. Brazil
- 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.6.2. Mexico
- 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.6.3. Argentina
- 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.7. MEA
- 5.7.1. Saudi Arabia
- 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.7.2. South Africa
- 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.7.3. UAE
- 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 5.7.4. Kuwait
- 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.2. Market Participant Categorization
- 6.2.1. Medtronic plc
- 6.2.1.1. Company overview
- 6.2.1.2. Financial performance
- 6.2.1.3. Product benchmarking
- 6.2.1.4. Strategic initiatives
- 6.2.2. St. Jude Medical, Inc.
- 6.2.2.1. Company overview
- 6.2.2.2. Financial performance
- 6.2.2.3. Product benchmarking
- 6.2.2.4. Strategic initiatives
- 6.2.3. Boston Scientific Corporation
- 6.2.3.1. Company overview
- 6.2.3.2. Financial performance
- 6.2.3.3. Product benchmarking
- 6.2.3.4. Strategic initiatives
- 6.2.4. CardioKinetix
- 6.2.4.1. Company overview
- 6.2.4.2. Financial performance
- 6.2.4.3. Product benchmarking
- 6.2.4.4. Strategic initiatives
- 6.2.5. Comed B.V.
- 6.2.5.1. Company overview
- 6.2.5.2. Financial performance
- 6.2.5.3. Product benchmarking
- 6.2.5.4. Strategic initiatives
- 6.2.6. Edwards Lifesciences Corporation
- 6.2.6.1. Company overview
- 6.2.6.2. Financial performance
- 6.2.6.3. Product benchmarking
- 6.2.6.4. Strategic initiatives
- 6.2.7. LivaNova PLC
- 6.2.7.1. Company overview
- 6.2.7.2. Financial performance
- 6.2.7.3. Product benchmarking
- 6.2.7.4. Strategic initiatives
- 6.2.8. Abbott Laboratories
- 6.2.8.1. Company overview
- 6.2.8.2. Financial performance
- 6.2.8.3. Product benchmarking
- 6.2.8.4. Strategic initiatives
- 6.2.9. JenaValve Technology, Inc.
- 6.2.9.1. Company overview
- 6.2.9.2. Financial performance
- 6.2.9.3. Product benchmarking
- 6.2.9.4. Strategic initiatives
- 6.2.10. Biomerics, LLC
- 6.2.10.1. Company overview
- 6.2.10.2. Financial performance
- 6.2.10.3. Product benchmarking
- 6.2.10.4. Strategic initiatives